Cipher Pharma announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharma, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions. For full story link to Smartbrief
Monday, 11 August 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment